Defining the balance of risk and benefit in the era of genomics and proteomics.


Journal Article

The ability to measure the function of genes and proteins has spawned the construct of personalized medicine, in which patients' own risks and preferences are used to choose diagnostic and therapeutic strategies. The complexity of clinical data required to guide personalized medicine calls for improvements in our system of clinical research, including (1) overhauling it to produce networks that can do adequate-size pragmatic trials; (2) synchronization of regulatory and payment systems to encourage adequate studies; and (3) an investment in education of providers and patients to improve the understanding of the probabilistic predictions forming the basis of personalized medicine.

Full Text

Cited Authors

  • Califf, RM

Published Date

  • January 2004

Published In

Volume / Issue

  • 23 / 1

Start / End Page

  • 77 - 87

PubMed ID

  • 15002630

Pubmed Central ID

  • 15002630

International Standard Serial Number (ISSN)

  • 0278-2715

Digital Object Identifier (DOI)

  • 10.1377/hlthaff.23.1.77


  • eng

Conference Location

  • United States